Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients

Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients

This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment S...

Full description

Saved in:
Bibliographic Details
Main Authors: Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay
Format: Article
Language:English
Published: Mary Ann Liebert 2024-11-01
Series:Neurotrauma Reports
Subjects:
aFGF
motor score
MRI
myelomalacia
spinal cord injury
Online Access:https://www.liebertpub.com/doi/10.1089/neur.2024.0063
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF’s potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, p = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (p < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.
ISSN:2689-288X

Similar Items